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Background:  It  remains  unknown  whether  the  time  course  of  the antiplatelet  effects  of  clopidogrel  differs
according  to  cytochrome  P450  (CYP)  2C19 phenotype  in Japanese  patients  with  acute  coronary  syndromes
(ACS).
Methods  and  results:  Platelet  reactivity  was  serially  assessed  by VerifyNow-P2Y12  assay  (Accumetrics,  San
Diego, CA,  USA).  Results  were  expressed  as P2Y12-reaction-units  (PRU)  in 177  patients  with  ACS  who
underwent  stent  implantation  and  received  aspirin  plus  a 300-mg  loading  dose  of clopidogrel  followed
by  75  mg/day.  High  on-clopidogrel  treatment  platelet  reactivity  (HTPR)  was  deﬁned  as  PRU  >  235. On  the
basis  of  the CYP2C19*2  and  *3 alleles,  46 patients  (26.0%)  were  classiﬁed  as  extensive  metabolizers  (EM),
103 (58.2%)  as  intermediate  metabolizers  (IM),  and  28 (15.8%)  as poor  metabolizers  (PM). At  <7  days,
the  PRU  level  (232 ± 102  vs.  279  ±  70,  308  ±  67,  p < 0.001)  and  the  incidence  of  HTPR  (49% vs. 74%,  86%,
p  =  0.001)  was  lower  in EM  than  in IM  and  PM.  At 14–28  days  the effects  of CYP2C19  polymorphisms  on
PRU  levels  increased  in a  stepwise  fashion  (168  ± 99  vs.  213  ±  77 vs.  278  ± 69,  p < 0.001),  and  EM and  IM
had  lower  percentages  of HTPR  than  PM  (28%,  37%  vs. 73%,  p <  0.001).  There  was  no  signiﬁcant  difference
in  the cumulative  frequency  of  12-month  adverse  cardiovascular  events  among  3  phenotypes  (16.5%,
14.1%,  9.2%;  p  =  0.67).
Conclusion:  About  three  quarters  of Japanese  patients  with  ACS  carried  CYP2C19  variant  alleles.  The
majority  of IM  and PM  had increased  platelet  reactivity  during  the  early  phase  of  ACS.  Although  HTPR
was  frequently  observed  even  14–28  days  after  standard  maintenance  doses  of clopidogrel  in PM,  the
omes
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Dual antiplatelet therapy (DAPT) with aspirin and clopido-
rel has been a cornerstone of medical treatment for patients
ho have acute coronary syndromes (ACS) or undergo percuta-
eous coronary intervention (PCI) [1,2]. However, the response
o clopidogrel varies widely among individuals [3], and high
n-clopidogrel treatment platelet reactivity (HTPR) is associated
ith adverse cardiovascular events, including stent thrombosis
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apan. Tel.: +81 45 261 5656; fax: +81 45 261 9162.
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ttp://dx.doi.org/10.1016/j.jjcc.2013.03.006 did  not  differ,  irrespective  of  CYP2C19  genotype.
anese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
after implantation [4,5]. Clopidogrel is a prodrug that must be
metabolized by the cytochrome P (CYP) 450 enzyme system to
generate active metabolites. Metabolic activation by CYP2C19 is
crucial for generation of such metabolites. Several gene variants
are associated with reduced or enhanced CYP2C19 activity, how-
ever, CYP2C19*2 and CYP2C19*3 are the major mutant alleles
of CYP2C19 that account for >99% of loss-of-function (LOF)
alleles in Asian populations [6,7]. Carriers of the CYP2C19*2
and/or CYP2C19*3 LOF alleles have a reduced pharmacodynamic
response to clopidogrel and worse clinical outcomes as com-
pared with noncarriers in Asian countries [8,9]. However, it is
unknown whether the time course of the antiplatelet effects of
clopidogrel differs according to CYP2C19 phenotype in Japanese
patients with ACS. We  serially assessed platelet reactivity in the
early and late phases of ACS according to CYP2C19 phenotypes
vier Ltd. All rights reserved.
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n Japanese patients who underwent coronary stent implanta-
ion.
ethods
tudy population
We  conducted a prospective, multicenter study designed to
ssess platelet function serially according to CYP2C19 genotype
n ACS patients who were scheduled to undergo coronary stent
mplantation treated with DAPT. A total of 300 consecutive patients
ere assessed for eligibility. Patients who met the inclusion cri-
eria were registered to randomized study to assess the impacts
f omeprazole and famotidine on the antiplatelet effects of clo-
idogrel (n = 180). Patients excluded from the randomized study
ere registered to cohort study (n = 88). Finally, 177 patients
ere analyzed in the present study in whom platelet reactiv-
ty was serially assessed by VerifyNow-P2Y12 (Accumetrics, San
iego, CA, USA) assay and CYP2C19 phenotype was  determined
Fig. 1).
The inclusion criteria for patients with ST-segment elevation
yocardial infarction (STEMI) were ischemic symptoms that lasted
or 20 min  or more, ST-segment elevation of ≥1 mm in ≥2 continu-
us precordial leads or in ≥2 limb leads, elevated levels of a cardiac
iomarker of necrosis, and undergoing primary PCI within 12 h after
nset of symptoms. ACS patients without persistent ST-segment
levation had to have ischemic symptoms lasting ≥10 min  and
ccurring within 72 h before the study entry, and either ST-segment
eviation of ≥1 mm or elevated levels of a cardiac biomarker of
ecrosis.
Exclusion criteria included major bleeding events within 7 days
efore enrollment, a serum hemoglobin level of <11 g/dl or >17 g/dl,
 platelet count of <120,000/mm3 or >500,000/mm3, hematologic
r malignant disease, a serum creatinine level of >2.0 mg/dl,
evere liver dysfunction, or the use of oral anticoagulant agents,
Assessed for eligibility
(n=300)
Randomized study
(n=180)
Analyzed
(n=126)
Discontinuation of DAPT  (n=32)
•CABG performed (n=6)
•Warfarin started (n=5)
•No stent implant (n=21)
Incomplete platelet function
tests or genotyping (n=22)
Analyzed
(n=177)
Fig. 1. Flow diagram. CABG, coronary artery bypadiology 62 (2013) 158–164 159
thienopyridine derivatives, cilostazol, glycoprotein IIb/IIIa
inhibitors, or ﬁbrinolytic agents within 7 days before enroll-
ment. Patients were also excluded if they did not receive stent
implantation within 14 days after symptom onset, if they under-
went coronary artery bypass grafting (CABG), or if they received
oral anticoagulant agents during the study period.
Antiplatelet therapy and PCI procedure
All patients were required to receive aspirin 100 mg/day indef-
initely and a 300-mg loading dose of clopidogrel followed by
75 mg/day for at least 12 months. A 200-mg loading dose of
aspirin was  administered only in aspirin-naïve patients. Primary
PCI was  performed immediately after a loading dose of clopid-
ogrel was  administered. Planned PCI was performed at least 6 h
after patients received the loading dose of clopidogrel. PCI was
performed in a standard manner. The choice of vessels treated,
devices used (including stent type), and adjunctive medication
administered to support PCI was left to the discretion of the
treating physicians. At the time of the study, glycoprotein IIb/IIIa
inhibitors and intravenous anticoagulants other than unfraction-
ated heparin were not approved for use in patients with ACS
or stent implants (or both) in Japan. Intravascular ultrasound
(IVUS) examination was performed at the end of PCI procedure
in all study patients. Intracoronary isosorbide dinitrate (2 mg)
was administered before IVUS examination to prevent coronary
spasm. All coronary angiograms and IVUS ﬁndings were evalu-
ated by a single cardiologist who was blinded to all other clinical
data.
Platelet function tests and genotypingPlatelet function tests were serially performed with the use
of the VerifyNow P2Y12/aspirin assays before clopidogrel loading
(baseline), within 7 days after clopidogrel loading (early phase),
Cohort study
(n=88)
Analyzed
(n=51)
Discontinuation of DAPT (n=21)
•CABG performed (n=4)
•Warfarin started (n=2)
•No stent implant (n=15)
Incomplete platelet function 
tests or genotyping (n=16)
Exclusion criteria (n=32)
•Previous warfarin or thienopyridine use (n=7)
•Recent bleeding history (n=2)
•Hematological criteria (n=10)  
•Renal insufficiency (n=13)
ss grafting; DAPT, dual antiplatelet therapy.
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nd at 14–28 days (late phase). If platelet function test was  per-
ormed after stent implantation, it was required that the time
rom PCI to blood sampling was >96 h in order to avoid the inﬂu-
nce of heightened platelet reactivity induced by PCI procedure.
hus, the second platelet function test was done 5–7 days after
lopidogrel loading in patients with primary PCI. Medical treat-
ent was not changed according to the results of VerifyNow
2Y12/aspirin assays. CYP2C19 genotypes were determined. The
ttending physician was blinded to the results of CYP2C19 geno-
ype. The institutional review boards of all participating centers
pproved the study protocol, and all patients provided written
nformed consent and agreed to CYP2C19 genotyping.
erifyNow P2Y12/aspirin assays
Whole blood was collected from peripheral venous sites using
 21-gauge or larger needle into a Greiner blood collection tube
GP-CD018) containing 3.2% sodium citrate, after ﬁrst discarding
he initial approximately 2 mL  collected. The VerifyNow system®
s a rapid point-of-care platelet function test system. The Veri-
yNow P2Y12 test measures ADP-induced platelet aggregation and
eports results as P2Y12 Reaction Units (PRU). A second channel
n the test device activates platelets through the thrombin recep-
or pathway, which is P2Y12-receptor-independent and provides
 simultaneous estimate of baseline total platelet function, which
s reported as “Base PRU.” The percent inhibition of ADP-induced
latelet aggregation is calculated from the PRU and Base PRU val-
es. Because it has been reported that a cutoff of HTPR is determined
s 230–240 PRU based on receiver-operating characteristic curve
nalysis in Western populations [10–14], HTPR was  deﬁned as
RU > 235 in the present study, despite a lack of consensus on the
utoff value associated with clinical outcomes in Japanese patients
ith ACS [15]. In a similar manner, the VerifyNow Aspirin test con-
ains arachidonic acid to activate the platelets and measure the
ntiplatelet effect of aspirin. Results from the VerifyNow Aspirin
est are reported as aspirin reaction units (ARU). Aspirin resistance
as deﬁned as ARU > 550 [16].
enotyping
CYP2C19 genotypes were determined by Invader assay. Geno-
yping was performed for CYP2C19*2 (rs4244285, c.681G>A) and
YP2C19*3 (rs4986893, c.636G>A) variants. Genomic DNA was
xtracted from whole blood using a commercially available QIAamp
NA Blood Mini kit (Qiagen, Venlo, The Netherlands). Previous
tudies have reported that the CYP2C19*2 and CYP2C19*3 alleles
re frequent, whereas the CYP2C19*17 allele is rare in Asians
17,18]. Patients were classiﬁed into categories of metabolizer
henotypes with the use of established common-consensus star
llele nomenclature. Thus, patients without a *2 or *3 allele (non-
arriers) were classiﬁed as “extensive metabolizers (EM),” those
ith one *2 or *3 allele were classiﬁed as “intermediate metabo-
izers (IM),” and those with two *2 or *3 alleles were classiﬁed as
poor metabolizers (PM).” Carriers of at least 1 CYP2C19 LOF allele
ere classiﬁed as “CYP2C19 LOF allele carriers.”
linical outcomes
Follow-up visits were conducted at participating centers for at
east 12 months. Patients who became unable or were unwilling to
ome to the hospital were contacted by telephone. Adverse cardio-
ascular events were deﬁned as death from cardiovascular causes,
pontaneous myocardial infarction, stent thrombosis, ischemic
troke, target vessel revascularization, or non-target vessel revas-
ularization. Myocardial infarction was deﬁned according to the
niversal deﬁnition proposed in 2007 [19]. Stent thrombosis wasdiology 62 (2013) 158–164
deﬁned as deﬁnite or probable according to the Academic Research
Consortium deﬁnitions [20]. Non-target vessel revascularization
was deﬁned as the procedure to newly diagnosed stenosis (≥75%)
or occlusion on the coronary angiogram. All the procedures were
carried out at the discretion of the operator. Planned PCI for residual
stenotic lesion was not considered an adverse event. Similar to tri-
als such as REPLACE-2 [21], non-CABG-related major bleeding was
deﬁned as symptomatic intracranial, intraocular, or retroperitoneal
hemorrhage, clinically overt blood loss including gastrointestinal
bleeding resulting in a decrease in hemoglobin by >3 g/dl, or bleed-
ing requiring transfusion of ≥2 units of red blood cells. The study
was designed and conducted by the authors. The sponsor had no
role in the design or conduct of the study, in the analysis of the
results, or in the decision to publish the paper.
Statistical analysis
Categorical variables are expressed as percentages and were
compared by the chi-square test. Allele frequencies were calcu-
lated, and departure from Hardy–Weinberg equilibrium was  tested
by the chi-square test. Continuous variables were compared by
one-factor analysis of variance and are reported as means ± SDs.
Potential predictors which were demographic, clinical, and angi-
ographic variables (shown in Tables 1 and 2) with p-values of <0.20
on univariate analysis were included in multivariate logistic regres-
sion analysis. Odds ratios (OR) and 95% conﬁdence intervals (CI)
were calculated. Event-free rates from the time of clopidogrel load-
ing were estimated by the Kaplan–Meier method and compared
with the use of the log-rank test. Values of p < 0.05 were consid-
ered to indicate statistical signiﬁcance. Data were analyzed with
SPSS 19 (SPSS, Inc., Chicago, IL, USA).
Results
Platelet reactivity was serially assessed and CYP2C19 genotypes
were determined in 177 patients with ACS who underwent stent
implantation and received aspirin and clopidogrel. There was no
signiﬁcant difference in the baseline characteristics between 126
patients in the randomized study and 51 patients in the cohort
study, except for the rates of medical history of proton pump
inhibitors (0% vs. 29%, p < 0.001) and H2 receptor antagonists (0%
vs. 14%, p < 0.001) (data not shown). The numbers of patients
carrying the CYP2C19*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3
genotypes were 46 (26.0%), 75 (42.4%), 28 (15.8%), 14 (7.9%), 13
(7.3%), and 1 (0.6%), respectively. The proportions of patients with
the CYP2C19*1, CYP2C19*2, and CYP2C19*3 polymorphisms were
55.1%, 32.8%, and 12.1%, respectively. Genotype frequency results
were consistent with Hardy–Weinberg equilibrium (p > 0.05). The
distribution of CYP2C19 phenotype was  as follows: 26.0% in EM,
58.2% in IM,  and 15.8% in PM.  The proportion of CYP2C19 LOF  allele
carriers was  extremely high (74.0%).
There were no signiﬁcant differences in patient characteristics
and angiographic ﬁndings among 3 phenotypes, except for the pro-
portion of current smokers (Table 1). Signiﬁcant difference was  not
observed in medication among 3 phenotypes. Omeprazole (73%)
was frequently prescribed among proton pump inhibitor-treated
patients (n = 86), whereas the rate of taking omeprazole was similar
among 3 phenotypes (Table 2). PRU levels at baseline were similar
among the 3 phenotypes. Time course of PRU levels from baseline
to the late phase among the 3 phenotypes is shown in Fig. 2. At <7
days (an average of 3.6 days), the PRU level (232 ± 102 vs. 279 ± 70,
308 ± 67, p < 0.001) and the incidence of HTPR (PRU > 235) (49% vs.
74%, 86%, p = 0.001) were lower in EM than in IM or PM.  At 14–28
days (an average of 19.9 days), the effects of CYP2C19 polymor-
phisms on PRU levels increased in a stepwise fashion (168 ± 99
Z. Nagashima et al. / Journal of Cardiology 62 (2013) 158–164 161
Table  1
Patient characteristics and angiographic ﬁndings.
EM (n = 46) IM (n = 103) PM (n = 28) p value
Age (years) 64 ± 12 65 ± 12 70 ± 10 0.06
Male  gender 87% 79% 75% 0.37
Body  mass index (kg/m2) 24 ± 4 24 ± 4 24 ± 3 0.95
History of hypertension 74% 66% 79% 0.35
History of diabetes mellitus 28% 20% 25% 0.55
History of dyslipidemia 63% 65% 68% 0.91
Current smokers 37% 48% 21% 0.03
Previous myocardial infarction 4% 4% 4% 0.98
Previous cerebral infarction 7% 2% 4% 0.36
3-Vessel disease 20% 13% 14% 0.41
Vessel treated 0.41
Left  main 4% 0% 0%
Left  anterior descending 45% 53% 52%
Left  circumﬂex 17% 15% 15%
Right coronary artery 34% 32% 33%
Primary PCI for STEMI patients 54% 56% 50% 0.83
Planned PCI for culprit artery 46% 44% 50% 0.83
Number of stents implanted 1.24 ± 0.52 1.23 ± 0.51 1.21 ± 0.63 0.98
Drug-eluting stents implanted 37% 28% 33% 0.57
Total  stent length (mm) 23 ± 10 23 ± 13 26 ± 15 0.64
Minimal stent diameter (mm)a 2.92 ± 0.51 3.07 ± 0.54 3.04 ± 0.58 0.74
IABP  use 7% 4% 0% 0.37
TIMI  ﬂow post-PCI < 3 2% 1% 0% 0.67
Ejection fraction at discharge (%) 57 ± 10 56 ± 9 55 ± 12 0.71
Values are percentages or means ± SDs. EM,  extensive metabolizers; IM,  intermediate metabolizers; PM,  poor metabolizers; PCI, percutaneous coronary intervention; STEMI,
S , throm
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cT-segment elevation myocardial infarction; IABP, intra-aortic balloon pump; TIMI
a Minimal stent diameter was measured with intravascular ultrasound.
s. 213 ± 77 vs. 278 ± 69, p < 0.001), and the rates of HTPR were
ower in EM and IM than that in PM (28%, 37% vs. 73%, p < 0.001).
hereas there was no signiﬁcant difference in PRU value at <7 days
etween IM and PM (p = 0.19), IM had signiﬁcantly lower PRU level
t 14–28 days compared with PM (p < 0.01). The rates of aspirin
esistance were low at <7 days and at 14–28 days in all 3 phenotypes
Table 3). On multivariate logistic regression analysis, IM (OR: 2.86,
I: 1.25–6.53, p = 0.01) and PM (OR: 5.65, CI: 1.51–21.03, p = 0.01)
ere both independent predictors of HTPR at <7 days, as were an
ge of >70 years (OR: 5.07, CI: 2.05–12.53), diabetes mellitus (OR:
.62, CI: 1.01–6.75), and current smoker (OR: 0.41, CI: 0.18–0.93)
Table 4a). In contrast, PM (OR: 6.59, CI: 2.13–20.31, p = 0.001) and
n age of >70 years (OR: 2.18, CI: 1.05–4.50) were independent pre-
ictors of HTPR at 14–28 days, whereas IM was  not (OR: 1.39, CI:
.61–3.13, p = 0.42) (Table 4b). There was no signiﬁcant difference
able 2
lood examinations and medications.
EM (n = 46) 
Blood examinations at baseline
Leukocytes 8753 ± 3048 
Hemoglobin 14.5 ± 1.8 
Platelet count 22.2 ± 4.8 
Renal insufﬁciency* 33% 
Medications at 14–28 days
Aspirin 100% 
Clopidogrel 100% 
Calcium channel blockers 17% 
Beta-blockers 59% 
ACE  inhibitors 43% 
Angiotensin II receptor blockers 17% 
Statins 93% 
CYP3A4 metabolized statins† 36% 
Proton pump inhibitors 56% 
Omeprazole 70% 
Lansoprazole 15% 
Rabeprazole 15% 
alues are percentages or means ± SDs. EM,  extensive metabolizers; IM,  intermediate 
ytochrome P450.
* Renal insufﬁciency was  deﬁned as an estimated glomerular ﬁltration rate of <60 (mL/
† CYP3A4 metabolized statins mean simvastatin and atorvastatin.bolysis in myocardial infarction.
in the cumulative frequency of adverse cardiovascular events at 12
months among 3 phenotypes (16.5%, 14.1%, 9.2%; p = 0.67) (Fig. 3).
The most common adverse event was  target or non-target vessel
revascularization. Only 2 patients in IM had myocardial infarction
or ischemic stroke, and stent thrombosis did not occur.
Discussion
In our study, the prevalence of CYP2C19 LOF allele carriers was
extremely high (74.0%) among Japanese patients with ACS. The
presence of even 1 CYP2C19 LOF allele was  an independent pre-
dictor of HTPR within 7 days after clopidogrel loading (early phase
of ACS). In contrast, only the presence of 2 CYP2C19 LOF alleles
was an independent predictor of HTPR at 14–28 days (late phase
of ACS). Although HTPR was frequently observed even 14–28 days
IM (n = 103) PM (n = 28) p value
9053 ± 2707 7630 ± 1969 0.05
14.2 ± 1.5 13.8 ± 1.4 0.16
21.4 ± 5.3 21.4 ± 4.7 0.67
31% 36% 0.89
100% 100% –
100% 100% –
19% 39% 0.05
56% 36% 0.11
50% 36% 0.34
17% 14% 0.91
86% 88% 0.46
33% 46% 0.47
46% 42% 0.44
79% 58%
13% 25% 0.61
8% 17%
metabolizers; PM,  poor metabolizers; ACE, angiotensin-converting enzyme; CYP,
min/1.73 m2).
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(U)
200
baseline  < 7 days  14-28 days
100
300
400
EM  
IM  
PM  
* p<0.01  vs baseline
† p<0.01  vs < 7 d ays
* *    
* †
*  * †
* * p<0.05 vs baseline
Fig. 2. Time course of P2Y12 reaction units (PRU) measured by VerifyNow P2Y12
assay. The mean PRU level signiﬁcantly decreased from baseline to the late phase
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Table 4a
Predictors of HTPR at <7 days.
OR (95%CI) p
Phenotype
PM vs. EM 5.65 (1.51–21.03) 0.01
IM vs. EM 2.86 (1.25–6.53) 0.01
Age  > 70 years 5.07 (2.05–12.53) <0.001
History of diabetes mellitus 2.62 (1.01–6.75) 0.04
Current smoker 0.41 (0.18–0.93) 0.03
Table 4b
Predictors of HTPR at >14 days.
OR (95%CI) p
Phenotype
PM vs. EM 6.59 (2.13–20.31) 0.001
IM  vs. EM 1.39 (0.61–3.13) 0.42
Age  > 70 years 2.18 (1.05–4.50) 0.03
Obesitya 1.65 (0.77–3.48) 0.19
Potential predictors, which were demographic, clinical, and angiographic variables
with p-values of <0.20 on univariate analysis, were included in a multivariate logistic
regression analysis. HTPR, high on-treatment platelet reactivity; OR, odds ratio; CI,
T
P
V
un  course of time in EM and IM,  although it remained unchanged during the study
eriod in PM.  Data are expressed as mean and standard deviations. EM,  extensive
etabolizers; IM,  intermediate metabolizers; PM,  poor metabolizers.
fter standard maintenance doses of clopidogrel in PM,  the inci-
ence of adverse outcomes did not differ, irrespective of CYP2C19
enotype.
The addition of clopidogrel to aspirin reduces ischemic events
uring and after ACS and PCI. However, recurrent ischemic events
ncluding stent thrombosis, remain a major concern even in
atients who receive DAPT. Several studies have demonstrated a
elation between HTPR and adverse cardiovascular events [4,5].
ariable and poor responses to clopidogrel can be explained in part
y single nucleotide polymorphisms of genes encoding CYP2C19
soenzymes with different activities [22]. A meta-analysis demon-
trated that the presence of even 1 reduced-function CYP2C19
llele was associated with a signiﬁcantly increased risk of adverse
ardiovascular events (particularly stent thrombosis) in patients
ho receive clopidogrel [23]. Most episodes of stent thrombosis
ccurred within the ﬁrst 30 days (especially within the ﬁrst 7 days)
fter stent implantation. The results of recent clinical trials sug-
est that intensive platelet inhibition is prerequisite to preventing
able 3
latelet function measurements and clinical outcomes according to CYP2C19 phenotype.
EM (n = 46) 
VerifyNow P2Y12 assay
PRU at baseline 308 ± 80 
PRU  at <7 days 232 ± 102 
PRU  > 235 (%) 49% 
Percent inhibition (%) 32.7 ± 24.8 
Time  to the second blood sampling (days) 3.8 ± 2.9 
PRU  at 14–28 days 168 ± 99 
PRU  >235 (%) 28% 
Percent inhibition (%) 51.0 ± 25.9 
Time  to the third blood sampling (days) 20.0 ± 6.0 
VerifyNow aspirin assay
ARU at <7 days 445 ± 65 
ARU  > 550 (%) 5% 
ARU  at 14–28 days 432 ± 69 
ARU  > 550 (%) 9% 
12-Month adverse cardiovascular events (%) 16.50% 
Cardiovascular death 0.00% 
Myocardial infarction 0.00% 
Ischemic stroke 0.00% 
Target  vessel revascularization 15.20% 
Nontarget vessel revascularization 6.80% 
Major bleeding at 12 months (%) 2.20% 
alues are percentages or means ± SDs. EM,  extensive metabolizers; IM,  intermediate me
nits.
* p < 0.01 vs. EM.
† p < 0.01 vs. IM.conﬁdence interval; EM,  extensive metabolizers; IM,  intermediate metabolizers;
PM,  poor metabolizers. HTPR was  deﬁned as P2Y12 reaction units > 235.
a Obesity was  deﬁned as body mass index > 25 (kg/m2).
cardiovascular events, including early stent thrombosis, in patients
with ACS who receive early invasive treatment [24–26]. However,
there are few reports serially assessing the antiplatelet effects of
clopidogrel according to CYP2C19 phenotype in patients with ACS.
The present study showed that carriers of at least 1 CYP2C19 LOF
allele (IM or PM), older age, and diabetes mellitus were associ-
ated with HTPR in the early phase of ACS. These results suggest
that platelet reactivity in the early phase is inﬂuenced not only by
CYP2C19 polymorphisms, but also by non-genetic factors, which
are known to predict baseline platelet reactivity. HTPR is more
frequent in patients with diabetes mellitus treated with DAPT com-
pared with nondiabetic patients [27]. Cigarette smoking induces
CYP1A2, which converts clopidogrel into its active metabolite and
leads to the beneﬁcial effect of clopidogrel on clinical outcomes
[28]. In the early phase of ACS, both IM and PM had higher platelet
IM (n = 103) PM (n = 28) p value
303 ± 66 298 ± 52 0.83
279 ± 70* 308 ± 67* <0.001
74%* 86%* 0.001
18.9 ± 14.8* 11.5 ± 14.5*,† <0.001
3.7 ± 2.8 3.1 ± 2.5 0.52
213 ± 77* 278 ± 69*,† <0.001
37% 73%*,† <0.001
37.8 ± 20.9* 22.2 ± 16.5*,† <0.001
20.2 ± 6.3 18.3 ± 5.9 0.36
450 ± 54 463 ± 68 0.46
6% 15% 0.21
439 ± 62 447 ± 54 0.61
8% 8% 0.96
14.10% 9.20% 0.67
0.00% 0.00% –
0.70% 0.00% –
0.70% 0.00% –
7.80% 7.10% 0.37
7.60% 3.60% 0.69
2.90% 3.60% 0.93
tabolizers; PM, poor metabolizers; PRU, P2Y12 reaction units; ARU, aspirin reaction
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Fig. 3. Event-free rates from the time of clopidogrel loading according to CYP2C19
phenotype. Adverse cardiovascular events were deﬁned as death from cardio-
vascular causes, spontaneous myocardial infarction, stent thrombosis, ischemic
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eactivity compared with EM,  although platelet function was  mod-
rately inhibited in IM who received extended treatment with
lopidogrel beyond 7 days. IM still have 1 functional copy of the
llele, and platelet reactivity might gradually decrease until the late
hase, suggesting that a higher dose of clopidogrel or the addition
f cilostazol to DAPT may  be effective [29,30]. However, PM may
ot respond to higher doses [31]. An alternative antiplatelet agent,
uch as prasugrel, may  increase the degree of platelet inhibition
32,33]. Large randomized trials have failed to conﬁrm clinical efﬁ-
acy of tailoring antiplatelet therapy according to results of platelet
unction tests [34,35]. A recent trial showed no signiﬁcant improve-
ent in ischemic outcomes and no better safety outcomes with a
trategy of monitoring and drug adjustment as compared with a
onventional treatment strategy. However, primary PCI for STEMI
as excluded and only 27% of patients presenting with ACS without
T-segment elevation were included in the study [36]. There is the
ossibility of a beneﬁt of platelet function testing in a higher-risk
opulation.
The prevalence of the CYP2C19*2 allele is higher in Asians (30%)
han in Westerners (about 15%), whereas the CYP2C19*3 allele is
ound in an appreciable proportion of Asians (10–20%), but is rare
n Caucasians (0.04%) [6]. CYP2C19 LOF genotype was shown to be
 strong determinant of adverse cardiovascular events in Korean
atients [8], whereas the relation between CYP2C19 genotype and
he magnitude of risk has been inconsistent in Western studies
23,37]. The present study showed that PM and older age were
ndependent predictors of HTPR in the late phase of ACS, consistent
ith the results of the Korean trial [8]. There are considerable eth-
ic differences in the distribution of CYP2C19 polymorphisms and
he magnitude of response to clopidogrel, and CYP2C19 genotype
s signiﬁcantly associated with HTPR in Asian patients. Despite this
ssociation, however, data from local registries indicate that the
ncidence of stent thrombosis is lower in Japanese patients (0.3% at
0 days, 0.26%/year) than in Caucasian patients [38,39]. It is difﬁcult
o explain the apparent contradiction between the high prevalence
f HTPR and the low incidence of thrombotic events after stent
mplantation among Asians. One possible explanation is that Asians
ave a favorable endogenous thrombolytic proﬁle, whereas West-
rners are in a prothrombotic state [40], induced by heightened
latelet reactivity, hypercoagulability, endothelial dysfunction, and
nﬂammation [41]. Modest platelet inhibition may  be enough todiology 62 (2013) 158–164 163
avoid thrombotic events in Japanese patients. Another explanation
is that aspirin may  have an important role in thrombotic events.
Among Japanese patients with stent thrombosis, the interval from
discontinuation of DAPT to onset of stent thrombosis was short (13
days), however, the interval from discontinuation of thienopyridine
alone to onset of stent thrombosis was  long (314 days) [42]. The low
rate of aspirin resistance in the present study might be related to
the low incidence of thrombotic events in Japanese patients. Other
genetic and environmental factors, including angiographic and pro-
cedural characteristics, may  play an important role in recurrent
ischemic events in patients with ACS who undergo stent implanta-
tion.
Limitations
Our study had several limitations. First, the sample size was
too small to evaluate clinical outcomes. However, our results sug-
gested that the incidence of thrombotic events was low in Japanese
ACS patients treated with DAPT who  underwent stent implanta-
tion, despite the high prevalence of CYP2C19 polymorphisms and
HTPR. In addition, the PRU threshold was  deﬁned as PRU > 235 in the
present study. Recent studies in Korean populations have suggested
a higher cutoff of HTPR (252–274) compared with Western stud-
ies [43,44]. A threshold value of on-treatment platelet reactivity
might depend on the subset of patients studied, clopidogrel loading
dose, and timing of blood sampling. Further studies are needed to
determine the optimal cutoff of HTPR based on receiver-operating
characteristic curve analysis in Japanese patients. Moreover, the
endpoint of our study was a surrogate marker, PRU value. Whether
HTPR is a modiﬁable risk factor or simply a marker of risk remains a
matter of debate [34,45]. Furthermore, the time window of platelet
function testing of the acute phase was wide. We performed the
second platelet function test between 6 h and 7 days after clo-
pidogrel loading, however, there was no difference in the time to
measurement among 3 phenotypes. Finally, we  did not evaluate
active metabolites of clopidogrel, markers of platelet activation, or
other genetic variants.
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